Follow
Sarah Overby
Sarah Overby
Postdoctoral Researcher, Universitätsklinikum Frankfurt
Verified email at med.uni-frankfurt.de
Title
Cited by
Cited by
Year
RNA-mediated therapies in myotonic dystrophy
SJ Overby, E Cerro-Herreros, B Llamusi, R Artero
Drug Discovery Today 23 (12), 2013-2022, 2018
482018
Therapeutic potential of antagomiR-23b for treating Myotonic Dystrophy
E Cerro-Herreros, I González-Martínez, N Moreno-Cervera, S Overby, ...
Molecular Therapy-Nucleic Acids 21, 837-849, 2020
372020
MicroRNA-Based Therapeutic Perspectives in Myotonic Dystrophy
A López Castel, SJ Overby, R Artero
International journal of molecular sciences 20 (22), 5600, 2019
322019
Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model
SJ Overby, E Cerro-Herreros, I González-Martínez, MA Varela, ...
Molecular Therapy-Nucleic Acids 27, 1146-1155, 2022
142022
Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy
E Cerro-Herreros, I González-Martínez, N Moreno, J Espinosa-Espinosa, ...
Molecular Therapy-Nucleic Acids 26, 174-191, 2021
142021
BlockmiR AONs as Site-Specific Therapeutic MBNL Modulation in Myotonic Dystrophy 2D and 3D Muscle Cells and HSALR Mice
SJ Overby, E Cerro-Herreros, J Espinosa-Espinosa, I González-Martínez, ...
Pharmaceutics 15 (4), 1118, 2023
22023
Proof of Concept of Therapeutic Gene Modulation of MBNL1/2 in Myotonic Dystrophy
S Overby
12022
The system can't perform the operation now. Try again later.
Articles 1–7